The systematic review by González-González et al. [99] on B-Raf proto-oncogene serine and threonine kinase V600E mutation for ameloblastoma-targeted patients’ treatments summarizes that when surgical treatments for ameloblastomas are not an option, the discovery of these genomic biomarkers has revolutionized alternative therapies. This evidence concerns the gene BRAF and ameloblastoma.